长按二维码,关注官方公众号
You can share it to WeChat via the Qr code.
Enter the applet sharing event using WeChat scan.
With the greatly accelerated review and approval speed, and the market entry rules being clearer, especially influenced by the COVID-19 pandemic, the clinical demand for biotherapeutic products has become increasingly urgent. Therefore, biotherapeutic products have become a very important part impacting the world economy. However, opportunities and challenges coexist. For instance, the therapies developed are too concentrated on several popular targets, costs are too high, it is difficult to maintain quality consistency, and there lacks uniform quality standards for new treatment methods. These problems are not only faced by a certain biotech company, but are also needed to be overcome by the Chinese biopharmaceutical industry.
As the annual event with the highest participation rate of the Chinese biopharmaceutical companies, the 8th BioCon 2021 will be held at Shanghai Marriott Hotel Parkview on April 22-23, 2021. BioCon 2021 will have an in-depth analysis on the next-generation bispecific/polyclonal antibodies, ADCs, cell and gene therapy products, oncolytic virus products, nucleic acid vaccines and drugs. It will also focus on exploring the latest regulatory trends and the cutting-edge development strategies of biotherapeutics, from new drug discovery and design, intelligent/continuous/automated process development and optimization, cost reduction and efficiency enhancement to commercialization and market entry of biotherapeutics. This comprehensive analysis intends to build a professional and high-quality platform for domestic and foreign companies to discuss policies, exchange technologies, display products and develop businesses. BioCon 2021 aims to fully promote the development of the biopharmaceutical industry!
★ 7+ Forums & 100+ Reports. In-depth analysis on the hot topics and challenges concerned by the domestic and foreign biopharmaceutical companies
★ Interpret the latest domestic and foreign regulatory trends and analyze the review and market entry policies in China, thus accelerating the R&D and commercialization of biotherapeutic products
★ Focus on CMC and process development and optimization of next-generation bispecific/polyclonal antibodies, ADCs, cell and gene therapy products, oncolytic virus products, nucleic acid vaccines and drugs and accelerate industrialization
★ Share the latest case on drug discovery, technological platform development and translational medicine
★ Analyze key difficulties such as commercialization of proteins / antibodies / cell therapy products, on-site verification, and post-market process changes
★ Explore cost reduction and efficiency enhancement, establishment and application of future 4.0 factory and quality control and management of continuous production
周彩存，医学博士，博士生导师，主任医师，教授；上海市领军人才，享受国务院特殊津贴 现任同济大学附属上海市肺科医院肿瘤科主任，医学院肿瘤研究所所长 中国医促会胸部肿瘤分会主委，中国抗癌协会肺癌专业委员会常委，上海市抗癌协会肺癌分子靶向和免疫治疗专业委员会主委，中国抗癌协会肿瘤药物临床研究专业委员会副主任委员，中国医师协会肿瘤分会常委，上海市医师协会肿瘤分会副会长,CSCO理事，上海市医学会肿瘤分会副主任委员 (lung Cancer)副主编,(Translational Lung Cancer Research)主编
德国Tubingen大学获有机化学博士，后赴美国Vanderbilt大学从事博士后研究。加入恒瑞前，张连山博士先后在美国礼来等国际知名药企担任要职。自1988年至今，他从事多肽方法学和新药研发工作三十余年，在抗糖尿病药物方面极有造诣；目前已发表学术文章60余篇，申请专利130余篇。加入恒瑞后，他带领团队研发了一系列具有国际竞争力的创新药，其中6个1类创新药品种已获批上市，200多项临床研究正在国内外开展。
